Phase 2 Pulmonary Hypertension Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older
• People who have been diagnosed with intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts inside the liver), confirmed through a tissue or cell sample
• People whose cancer cannot be surgically removed, has come back, or has spread to other parts of the body
• People who have not yet received any systemic (whole-body) treatment, such as chemotherapy, for their advanced cancer
• People who have at least one tumour that can be measured using standard imaging guidelines
• People who are relatively well and able to carry out daily activities, as measured by a standard health scale (ECOG score of 0 or 1)
• People for whom enough tumour tissue is available before treatment starts, for review by a central laboratory
• People whose tumour tissue shows a specific protein marker result (CK5/6 H-score of 1.0 or higher), as tested by a central laboratory
• People whose liver, kidneys, and bone marrow are functioning well enough to meet the trial's laboratory requirements
• People who have a blocked bile duct must have had it successfully drained and their condition stabilised before joining
• People who are able to give written consent to participate

Who may not be able to join:

• People who have another type of primary cancer, including bile duct cancer outside the liver, gallbladder cancer, or cancer of the ampulla (a small opening where the bile duct meets the small intestine)
• People whose tumour tissue shows a CK5/6 H-score below 1.0
• People who have already received systemic treatment for advanced or metastatic disease
• People with active gastrointestinal bleeding, stomach ulcers, or a high risk of a hole developing in the stomach or bowel
• People who have recently had a serious heart or blood vessel event, such as a heart attack, stroke, uncontrolled high blood pressure, or severe heart failure
• People with a known allergy or sensitivity to celecoxib, sulfonamide medicines, anti-inflammatory medicines (NSAIDs), or aspirin — including those who have breathing problems triggered by aspirin
• People with an active autoimmune disease or any condition that would make treatment with pembrolizumab unsafe
• People with severely reduced kidney function
• People with advanced liver impairment classified as Child-Pugh class C
• People with an active infection that is not under control
• People who have any other condition that, in the treating doctor's judgement, would interfere with taking part in or interpreting the results of the trial

Important: Always verify eligibility with the trial site directly before applying.